The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clin. transl. oncol. (Print)
; 25(2): 417-428, feb. 2023.
Article
in En
| IBECS
| ID: ibc-215941
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Purpose To conduct a systematic review to analyse the performance of the sentinel lymph-node biopsy (SLNB) in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy, compared to axillary lymph-node dissection. Methods The more relevant databases were searched. Main outcomes were false-negative rate (FNR), sentinel lymph-node identification rate (SLNIR), negative predictive value (NPV), and accuracy. We conducted meta-analyses when appropriate. Results Twenty studies were included. The pooled FNR was 0.14 (95% CI 0.110.17), the pooled SLNIR was 0.89 (95% CI 0.860.92), NPV was 0.83 (95% CI 0.790.87), and summary accuracy was 0.92 (95% CI 0.900.94). SLNB performed better when more than one node was removed and double mapping was used. Conclusions SLNB can be performed in women with a node-negative tumour after neoadjuvant therapy. It has a better performance when used with previous marking of the affected node and with double tracer (AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Breast Neoplasms
/
Sentinel Lymph Node Biopsy
Limits:
Female
/
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Document type:
Article